Sanz Iñaki
Division of Rheumatology, Lowance Center for Human Immunology, Georgia Research Alliance Eminent Scholar in Human Immunology, 247 Whitehead Research Bldg. 615 Michael St., Atlanta, GA, 30322, USA,
Semin Immunopathol. 2014 May;36(3):365-75. doi: 10.1007/s00281-014-0430-z. Epub 2014 Apr 25.
B cells are central pathogenic players in systemic lupus erythematosus and multiple other autoimmune diseases through antibody production as well as antibody independent function. At the same time, B cells are known to play important regulatory functions that may protect against autoimmune manifestations. Yet, the functional role of different B cell populations and their contribution to disease remain to be understood. The advent of agents that specifically target B cells, in particular anti-CD20 and ant-BLyS antibodies, have demonstrated the efficacy of this approach for the treatment of human autoimmunity. The analysis of patients treated with these and other B cell agents provides a unique opportunity to understand the correlates of clinical response and the significance of different B cell subsets. Here, we discuss this information and how it could be used to better understand SLE and improve the rational design of B cell-directed therapies in this disease.
B细胞通过产生抗体以及抗体非依赖性功能，在系统性红斑狼疮和多种其他自身免疫性疾病中是核心致病因素。同时，已知B细胞发挥重要的调节功能，可能预防自身免疫表现。然而，不同B细胞群体的功能作用及其对疾病的贡献仍有待了解。特异性靶向B细胞的药物的出现，特别是抗CD20和抗BLyS抗体，已证明这种方法在治疗人类自身免疫性疾病方面的有效性。对接受这些及其他B细胞药物治疗的患者进行分析，为了解临床反应的相关性以及不同B细胞亚群的意义提供了独特的机会。在此，我们讨论这些信息以及如何利用它来更好地理解系统性红斑狼疮，并改进针对该疾病的B细胞定向疗法的合理设计。
